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ABSTRACT
Objective: To investigate the synovial tissue in patients
with rheumatoid arthritis (RA) treated with rituximab and
to identify possible predictors of clinical response.
Methods: A total of 24 patients with RA underwent
synovial biopsy before, 4 and 16 weeks after initiation of
rituximab treatment (without peri-infusional corticoster-
oids to prevent bias). Immunohistochemical analysis was
performed and stained sections were analysed by digital
image analysis. Linear regression analysis was used to
identify predictors of clinical response.
Results: The 28-joint Disease Activity Score (DAS28)
was unaltered at 4 weeks, but significantly reduced at
16 and 24 weeks. Serum levels of IgM-rheumatoid factor
(RF) decreased significantly at 24 weeks and anti-
citrullinated peptide antibody (ACPA) levels at 36 weeks.
Peripheral blood B cells were depleted at 4 weeks and
started to return at 24 weeks. Synovial B cells were
significantly decreased at 4 weeks, but were not
completely depleted in all patients; there was a further
reduction at 16 weeks in some patients. We found a
significant decrease in macrophages at 4 weeks,
which was more pronounced at 16 weeks. At that
timepoint, T cells were also significantly decreased.
The reduction of plasma cells predicted clinical
improvement at 24 weeks.
Conclusions: The results support the view that B cells
orchestrate local cellular infiltration. The kinetics of the
serological as well as the tissue response in clinical
responders are consistent with the notion that rituximab
exerts its effects in part by an indirect effect on plasma
cells associated with autoantibody production, which
could help explain the delayed response after rituximab
treatment.
Trial registration number: ISRCTN05568900.
Rheumatoid arthritis (RA) is a chronic inflamma-
tory disorder affecting synovial tissue in multiple
joints. Early treatment with disease-modifying
antirheumatic drugs (DMARDs) has become the
cornerstone of therapy. Recently, new biological
therapies, including rituximab, have become avail-
able. Rituximab is a chimaeric monoclonal anti-
body directed against the CD20 antigen expressed
by B cells, which significantly improves disease
symptoms in patients with high levels of disease
activity despite treatment with methotrexate
(MTX) or tumour necrosis factor (TNF) block-
ers.
1–3 This clinical effect strongly supports the
notion that B cells play a critical role in the
pathogenesis of RA, although the exact mechanism
of rituximab treatment in RA remains to be
elucidated.
We have previously shown that rituximab
treatment causes a rapid and specific decrease in
numbers of B cells at the primary site of
inflammation, the rheumatoid synovium,
4 which
was recently confirmed in another study.
5 The
early synovial tissue response varies between
patients, which is in contrast with the marked
B cell depletion observed in the peripheral blood of
nearly all patients with RA. Interestingly, in the
earlier, smaller studies there was no significant
decrease in numbers of inflammatory cells other
than synovial B cells 4–8 weeks after initiation of
treatment.
45
Currently, no data are available on the synovial
tissue response to rituximab treatment after more
prolonged follow-up and its predictive value related
to clinical improvement. The current study was
performed to investigate the kinetics of this
response in detail and to identify possible pre-
dictors of clinical response in patients with RA.
PATIENTS AND METHODS
Patients and treatment protocol
A total of 24 patients were included in this study
analysing synovial biopsies at three timepoints:
before treatment, at 4 weeks and 16 weeks after
initiation of rituximab treatment; 17 of these
patients participated in a previously reported study
on the synovial tissue response to rituximab at
4 weeks only.
4 The patients had active RA;
6 active
disease was defined as having >4 tender joints and
>4 swollen joints of 28 joints assessed, and at least
one of the following: erythrocyte sedimentation
rate (ESR) >28 mm/h, serum C-reactive protein
(CRP) levels >15 mg/litre, or morning stiffness
>45 min. In addition, patients needed to be
positive for IgM-RF and/or anti-citrullinated pep-
tide antibodies (ACPA) and have active arthritis
(defined by the presence of pain and swelling)
of a wrist, knee or ankle joint, amenable for
arthroscopy.
All study patients were on stable doses of MTX
(5–30 mg/week) for at least 28 days prior to
enrolment. Stable prednisone therapy ((10 mg/
day) and non-steroidal anti-inflammatory drug
(NSAID) treatments were allowed. All other
DMARDs and biological agents were withdrawn
at least 4 weeks prior to study inclusion, with a
washout period for leflunomide, infliximab, adali-
mumab and etanercept of .8 weeks prior to
randomisation. The study protocol was approved
by the Medical Ethics Committee of the Academic
Medical Center/University of Amsterdam, and all
patients gave written informed consent before
participation in the study.
Treatment consisted of two infusions of
1000 mg of rituximab (Roche, Woerden, The
Netherlands) on days 1 and 15 after premedication
Extended report
Ann Rheum Dis 2008;67:917–925. doi:10.1136/ard.2007.080960 917with 2 mg clemastine fumarate intravenously and 1000 mg
acetaminophen orally. Peri-infusional treatment with corticos-
teroids was not allowed, as this could have influenced the
features of synovial inflammation.
The 28-joint Disease Activity Score (DAS28)
7 was measured
every month after treatment. Serum levels of IgM-rheumatoid
factor (RF) and ACPA (anti-CCP2 ELISA, Immunoscan RA,
Mark 2, Euro Diagnostica, Arnhem, the Netherlands) were
determined at baseline and weeks 4, 16, 24 and 36 after
treatment. Synovial biopsies were obtained from the same
clinically involved joint at three timepoints: before as well as 4
and 16 weeks after the first infusion of rituximab.
Blood lymphocyte populations
Flow cytometry on fresh peripheral blood samples was
performed at baseline and at 4, 16 and 24 weeks after the first
rituximab infusion. B cells and T cell subsets were detected by
real-time fluorescence-activated cell sorting (FACS) using a
FACSCalibur Flow Cytometer (Becton Dickinson, San Jose,
California, USA) with antibodies against CD19, CD3, CD4 and
CD8 (all from Becton Dickinson). CD19 was chosen because of
its similar expression to CD20 on B cell subsets, without
interference with the circulating rituximab antibody. The lower
limit of detection of CD19+ B cells was set at 0.01610
9 cells/
litre.
Synovial biopsy
Serial synovial biopsies were collected by needle arthroscopy
from the same actively inflamed joint under local anaesthesia as
previously described,
8 before as well as 4 and 16 weeks after the
first infusion of rituximab. To minimise sampling error at least
six biopsy samples were obtained from different sites in the
joint during each procedure.
91 0 Specimens were directly
embedded en bloc in TissueTek OCT (Miles Diagnostics,
Elkhart, Indiana, USA) and subsequently snap-frozen in liquid
nitrogen.
Immunohistochemistry
From each frozen tissue block serial sections (5 mm) were cut
and stained with the following mouse monoclonal antibodies:
anti-CD3 (SK7; Becton Dickinson), anti-CD4 (SK3; Becton
Dickinson) and anti-CD8 (DK25; Dako, Glostrup, Denmark) to
detect T cells, anti-CD22 (CLB-B-ly; Central Laboratory of the
Netherlands Red Cross Blood Transfusion Service, Amsterdam,
the Netherlands) to detect B cells, anti-CD68 (EBM11; Dako) to
detect macrophages, anti-CD55 (clone 67; Serotec, Oxford, UK)
to detect fibroblast-like synoviocytes, anti-CD138 (clone B-B4;
Immunotech, Marseille, France) to detect plasma cells and anti-
CD23 (clone MHM6; Dako) as well as anti-CD21L (a kind gift
from Dr Y Liu, Schering-Plough, Dardilly, France) to detect
follicular dendritic cells (FDCs), as described previously.
41 11 2
Sections with non-assessable tissue, defined by the absence of
an intimal lining layer, were not analysed. For control sections,
the primary antibodies were omitted or irrelevant antibodies
were applied.
To determine the distribution of B cells and FDCs in
lymphocyte aggregates, we evaluated two separate tissue
sections (each section representing one level of the six biopsy
samples that were embedded en bloc), located 50 mm apart,
which were stained with the anti-CD22, anti-CD23 and anti-
CD21L antibodies. CD22 rather than CD19 was used to detect
B cells in tissue, as it results in more reliable staining on the
tissue level. The presence of FDCs was assessed by CD23
staining and subsequently confirmed by CD21L staining.
Digital image analysis
All sections were coded and randomly analysed by computer-
assisted image analysis using a Leica DM-RXA light microscope
anda programwrittenintheprogramminglanguage QUIPS with
specialised Qwin software (both from Leica, Cambridge, UK).
13 14
An independent observer (Marjolein Vinkenoog, Division of
Clinical Immunology and Rheumatology of the Academic
Medical Centre/University of Amsterdam, The Netherlands)
who was unaware of the clinical data performed the acquisition
and image analysis. For all markers, 18 high-power fields were
analysed, as previously described and validated.
15 CD68 expres-
sion was analysed separately in the intimal lining layer and the
synovial sublining. CD22 expression was analysed on two levels
as described above, and the mean number of B cells was used
for statistical analysis. Data are expressed as the number of cells
per mm
2, representing cell density.
Lymphocyte aggregates were counted and classified as
previously described.
16 Aggregates with a radius of 2–5 cells
were defined as grade 1, those with a radius of 5–10 cells were
graded as 2, and those with a radius of .10 cells were graded as
3. The total number of grade 1, 2 and 3 was added up per
section. The resulting figure was termed the total number of
aggregates.
Statistical analysis
Changes in the DAS28 were compared using the Student paired
t test. Changes in peripheral blood lymphocytes, synovial cell
populations, as well as serum levels of total IgM, total IgG, IgM-
RF and ACPA were compared using Wilcoxon signed rank test
for paired data. A mixed linear model was used as a repeated
measurements method to confirm the results of the separate
paired t test for analysis of changes in synovial parameters.
Correlations between changes in synovial cell populations,
serumIgM-RFand ACPA levelsand theDAS28betweenbaseline,
4 weeks and 16 weeks after treatment were determined by
Spearman correlation coefficient. Differences in baseline synovial
cell populations and changes in cell populations between
responders and non-responders to treatment were determined
by the Mann–Whitney U test for unpaired data.
For analysis of possible predictive biomarkers for clinical
response we calculated the Spearman correlation coefficient
between the change in DAS28 (between baseline and week 24)
and changes in B cells, T cells, plasma cells and intimal and
sublining macrophages (between baseline, 4 weeks and
16 weeks). For dichotomous analysis response was determined
as a decrease in DAS28 of >1.2 at 24 weeks
17 and also as
according to the European League Against Rheumatism
(EULAR) response criteria.
18
The Mann–Whitney U test for unpaired data was used to
compare the clinical response in patients with FDCs or
lymphocyte aggregates at baseline compare to those without.
Parameters that were significantly related to the decrease in
DAS28 were subsequently analysed by univariate linear regres-
sion analysis to assess the predictive value. Finally, these
parameters were analysed together with multiple linear regres-
sion analysis in a backward model.
RESULTS
Clinical and demographic features
Clinical and demographic details are shown in table 1.
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One patient withdrew from the study after 20 weeks because of
insufficient clinical response. For analysis related to response at
week 24 the observations from her week 20 visit were carried
forward. The DAS28 was unaltered at 4 weeks (peri-infusional
corticosteroids were not allowed), but there was a significant
decrease in DAS28 at 16 and 24 weeks (compared to baseline:
mean (SD) decrease of 1.6 (1.1) and 1.6 (1.6), respectively; both
p,0.001). At 24 weeks 16 of the 24 patients (67%) had a
decrease in DAS28 of at least 1.2. In all, 3 patients (13%) had a
good response according to the EULAR response criteria, 14
patients (58%) a moderate response and 7 patients (29%) did
not fulfil the EULAR response criteria.
Decreased IgM-RF and ACPA levels after rituximab treatment
The IgM-RF and ACPA levels were not available for the week 24
visit and week 36 for the patient who withdrew from the study
after 20 weeks because of insufficient clinical response. For
another patient the visit at week 36 was not performed because
of personal circumstances. Thus, serial IgM-RF and ACPA levels
were available for 22 patients.
There was a highly significant decrease in serum levels of
IgM-RF at 16 (p=0.006) and 24 weeks (p,0.001) after
treatment (fig 1). There was a trend towards lower ACPA
levels at 24 weeks with a statistically significant decrease after
36 weeks (p=0.015) (fig 1). At 24 weeks the serum levels of
IgM-RF and ACPA decreased significantly more than those of
their respective antibody classes (p=0.001 for IgM-RF com-
pared with total serum IgM; p=0.026 for ACPA compared with
total serum IgG levels).
Depletion of B cells in peripheral blood
CD19+ B cells in PB were undetectable 4 and 16 weeks after
rituximab treatment (table 2). Low numbers of B cells could be
measured in 3/24 patients at week 4 and 4/24 patients at week
16 (0.01610
9/litre). At 24 weeks B cells started to return in 13 of
23 analysed patients (median 0.01610
9/litre (IQR 0.00–0.02).
The total numbers of T cells and T cell subsets did not change
significantly after treatment (table 2).
The effects of rituximab are not limited to synovial B cells:
changes in plasma cells, T cells, FDCs and macrophages
Out of the total of 24 patients analysed, baseline biopsies of 2
patients did not pass synovial tissue quality control; of these
patients only samples taken after 4 and 16 weeks were included
in the analysis. In two other patients the biopsy samples taken
after 16 weeks and in one patient the biopsy taken after
4 weeks was of insufficient quality to be included in the
analysis.
Extension of the study population in the present study
confirmed our previous observation,
4 showing a highly sig-
nificant reduction of synovial B cells at 4 weeks, but not in all
patients (fig 2, table 2). Similar results were obtained when we
used anti-CD19 antibodies to detect synovial B cells by
immunohistochemistry (data not shown). There was no
statistically significant additional reduction of synovial B cells
at 16 weeks on the group level, but there was a clear trend
towards more pronounced B cell depletion in 7 of the 15
patients who had persistent B cells at week 4 (median 39 cells/
mm
2 (IQR 12–89) and 4 (0–22), at respectively 4 and 16 weeks
after rituximab infusion). In five patients there was clear
persistence of B cells (median 52 (IQR 9–551) and 101 (63–313)
at baseline and at 16 weeks, respectively).
Since B cells are precursors of plasma cells, and B cell
depletion could indirectly result in a decrease in short-lived
plasma cells associated with autoantibody production,
19 we
examined the consequences of rituximab treatment for plasma
cell numbers in the synovium. There was a marked reduction of
plasma cells in a subset of the patients (fig 2, table 2). On the
group level this change did not reach statistical significance due
to the variability of the response.
The number of T cells was unaltered at 4 weeks, but there
was a significant decrease in T cell numbers at 16 weeks (fig 2,
table 2). Consistent with the reduction of synovial B cells and
T cells (the major cell populations in the lymphocyte
aggregates), we observed a trend towards reduced numbers of
lymphocyte aggregates at 4 weeks with a significant decrease of
aggregates of all sizes at 16 weeks (fig 2, table 2). FDCs were
found in four patients at baseline, but were undetectable in all
patients 16 weeks after treatment. Hence, rituximab treatment
had a clear effect on lymphocyte aggregates and germinal
centres (defined by the presence of FDCs).
Of interest, we also found a significant decrease in intimal
macrophages at 4 weeks, which was even more pronounced at
16 weeks (fig 2, table 2). In addition, there was a trend towards
lower numbers of sublining macrophages at 4 weeks with a
statistically significant reduction at 16 weeks (fig 2, table 2).
Using repeated measurement methods for analysis of changes in
synovial cell populations between baseline and 4 and 16 weeks
after treatment yielded the same results as separate paired t test
analysis.
Persistence of B cells after 16 weeks was correlated with
persistence of plasma cells (r=0.70; p,0.001), T cells (r=0.69;
p,0.001), and lymphocyte aggregates (r=0.72; p,0.001) at the
same timepoint.
Changes in synovial plasma cells predict clinical response
Since the clinical response to rituximab treatment may be
variable, we studied whether changes in synovial cell popula-
tions were related to clinical improvement.
Of importance, there were no baseline characteristics of
the synovium that could significantly predict clinical response
to treatment, although there was perhaps a minor trend
towards more B cells at baseline in responders compared to
Table 1 Baseline characteristics of the study patients
Demographic
Median age, years (range) 55 (22–75)
Female, no. (%) 18 (75)
Disease status:
Median disease duration, years (range) 12 (0.9–50)
Erosive disease, no. (%) 24 (100)
Nodular disease, no. (%) 9 (38)
Median IgM-RF, kU/litre (IQR) 75 (46–159)
Median ACPA, kU/litre (IQR) 240 (95–1031)
Median DAS28, (IQR) 6.5 (1.1)
Median ESR, mm/h (IQR) 37 (19–55)
Median CRP, mg/dl (IQR) 24 (10–76)
Medications:
Median no. of previous DMARDs, (IQR) 4 (2–5)
Median no. of previous biological agents, (IQR) 2 (1–3)
Median methotrexate dosage, mg/week (IQR) 15 (10–25)
Corticosteroids, no. (%) 16 (67)
Median prednisone dosage, mg/day (IQR) 5 (0–10)
ACPA, anti-cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 28-joint
Disease Activity Score; DMARDs, disease-modifying antirheumatic drugs; ESR,
erythrocyte sedimentation rate; IQR, interquartile range; RF, rheumatoid factor.
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between baseline and 4 weeks or between 4 weeks and
16 weeks was not significantly different between responders
versus non-responders to treatment.
Additionally, no changes in other inflammatory cells between
baseline and 16 weeks after treatment differed between
responders and non-responders, although a trend was found
for plasma cells (p=0.115). As described above, the changes in
synovial cells other than B cells were found between 4 and
16 weeks rather than between baseline and 4 weeks, except for
intimal macrophages where there was already a reduction at
4 weeks (fig 2). In light of the kinetics of the changes shown in
table 2 and fig 2, we compared the decrease in synovial cell
populations other than B cells between 4 weeks and 16 weeks
in relationship to clinical response (fig 4). Of interest, the
change in plasma cells differed significantly between responders
and non-responders (p=0.002) (fig 4B and 5). Within the
clinical responder group there was a significant decrease in
plasma cells after treatment (p=0.005), but not so in non-
responders. Similarly, there was a significant difference in
reduction of intimal macrophages between responders and non-
responders (p=0.008; fig 4D), with a similar trend for sublining
macrophages (fig 4F).
Linear regression analysis was performed to establish the
predictive value of the changes in synovial cell populations for
the size of the clinical response after 24 weeks. Consistent with
the analyses described above, we found a positive correlation
between the change in intimal macrophages (r=0.51; p=0.04)
as well as plasma cells (r=0.46, p=0.003) between 4 and
16 weeks on the one hand and the decrease in DAS28 after
24 weeks on the other. Accordingly, linear regression analysis
revealed that the decrease in plasma cells between 4 and
16 weeks could predict the decrease in DAS28 at 24 weeks after
treatment (R
2=0.26, p=0.002). The reduction of macrophages
also showed a trend for predicting clinical improvement at week
24 in the univariate analysis (p=0.051), but when analysed
together with the decrease in plasma cells in a multiple linear
regression model, it was not an independent predictor of the
decrease in DAS28 (p=0.216, partial correlation 0.399).
When linear regression analysis was performed on the
combination of changes in plasma cells between 4 and 16 weeks
and the baseline DAS28 using multiple linear regression
analysis, the decrease in plasma cells continued to predict the
decease in DAS28 at week 24 (p=0.034), whereas the baseline
DAS28 alone could not predict the clinical response (p=0.623).
Interestingly, the change in plasma cell numbers was also
Figure 1 Change in levels of IgM-
rheumatoid factor (IgM-RF; A) and anti-
citrullinated peptide antibodies (ACPA; B)
before and during the 36 weeks after
initiation of rituximab treatment. The
circles represent outliers (values of more
than 1.5 box lengths from the upper or
lower edge of the box; the box length is
the interquartile range). *p,0.05,
**p,0.01.
Table 2 Cells in peripheral blood and synovial tissue obtained from patients with rheumatoid arthritis before, 4 and 16 weeks after rituximab
treatment
Before rituximab 4 weeks after rituximab p Value* 16 weeks after rituximab p Value{
Blood lymphocytes:
CD19 0.13 (0.09–0.19) ,0.01 (0.00–0.00) ,0.001 ,0.01 (0.00–0.00) ,0.001
CD3 1.32 (0.81–1.68) 1.17 (0.90–1.90) 0.78 1.26 (1.00–1.87) 0.49
CD3CD4 0.93 (0.52–1.14) 0.78 (0.63–1.35) 0.64 0.85 (0.69–1.22) 0.66
CD3CD8 0.29 (0.19–0.48) 0.34 (0.20–0.52) 0.51 0.34 (0.22–0.49) 0.38
Cellular markers in synovial tissue:
CD22 38 (3–158) 9 (0–39) 0.002 8 (0–40) 0.015
CD3 249 (119–845) 391 (62–1114) 0.65 130 (44–383) 0.010
CD4 403 (2–1702) 78 (15–1128) 0.92 152 (55–659) 0.068
CD8 8 (0–27) 3 (0–6) 0.67 1 (0–10) 0.048
CD138 137 (58–496) 174 (0–623) 0.71 76 (0–213) 0.48
CD68L 293 (93–502) 148 (66–346) 0.043 133 (18–215) 0.001
CD68SL 548 (134–1076) 434 (88–1291) 0.112 191 (52–563) 0.023
Aggregates 8 (0–32) 4 (0–24) 0.078 1 (0–2) 0.007
CD68+ macrophages were analysed separately in the intimal lining layer (L) and synovial sublining (SL). Values for peripheral blood lymphocytes are median (interquartile range
(IQR)) 10
9/litre, for cellular markers in synovium median (IQR) cells/mm
2. The total no. of lymphocyte aggregates (aggregates) was counted per section.
*Wilcoxon signed rank test for paired data between baseline and week 4. {Wilcoxon signed rank test for paired data between baseline and week 16.
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(r=0.52, p=0.03).
When we used the change in synovial cells between baseline
and 16 weeks, similar trends were observed. As noted above and
shown in table 2 and fig 2, the major changes in synovial cell
populations other than B cells were observed between 4 and
16 weeks after treatment, secondary to the changes in synovial
B cells.
Collectively, the results suggest that the clinical response can
be predicted by changes in cell types other than B cells,
especially the number of synovial plasma cells that are derived
from B cells. This change is also correlated to the reduction in
serum ACPA levels.
DISCUSSION
The results presented here confirm the previously reported
variable tissue response of B cells after rituximab treatment, in
contrast to the nearly complete depletion of B cells in the
peripheral blood. Moreover, this study shows for the first time
the secondary effects on cell populations other than synovial
B cells, supporting the concept that B cells orchestrate synovial
inflammation. In particular the change in short-lived synovial
plasma cells (derived from B cells) between 4 and 16 weeks after
initiation of treatment is related to the clinical response over
time. These findings are consistent with the kinetics of the
gradual clinical response and the slow but sure decrease in levels
of circulating antibodies observed after rituximab treatment.
Figure 2 Change in number of CD22+ B
cells (A), CD3+ T cells (B), lymphocyte
aggregates (C), intimal (D) and sublining
(E) CD68+ macrophages and CD138+
plasma cells (F) in synovial tissue.
Biopsies were obtained before, 4 and
16 weeks after initiation of rituximab
treatment. The circles represent outliers
(values of more than 1.5 box lengths from
the upper or lower edge of the box; the
box length is the interquartile range).
*p,0.05, **p,0.01.
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by different mechanisms. First, B cells may drive synovial
inflammation by production of autoantibodies;
20 they are the
precursors of short-lived plasma cells associated with produc-
tion of autoantibodies, such as IgM-RF and ACPA. Second,
B cells are effective antigen-presenting cells and activators of
T cells.
21 Third, B cells may promote synovial inflammation by
producing pro-inflammatory cytokines and chemokines.
22–24
Thus, depletion of B cells could interfere with different
mechanisms involved in the pathogenesis.
The results from the present study show that rituximab
treatment may indeed deplete B cells at the primary site of
inflammation, the synovium, although there is persistence of
synovial B cells in a subset of patients. The discrepancy with the
completeB celldepletion observedinperipheralbloodinnearly all
patients might be explained by the expression of protective
factors in the tissue, such as BLyS
25 and CD55 (decay-accelerating
factor (DAF)),
26 as well as the requirement for B cells to access the
circulation for efficient depletion. This difference underscores the
importance of analysis of different compartments to understand
the effects of treatment, as has also been shown after, for
example, Campath-1H treatment.
27 The variable response in the
synovial tissue with regard to B cell depletion suggests that the
standard therapeutic regimen is perhaps not optimal in all
patients. Of note, persistence of synovial B cells was related to
persistence of plasma cells. Future studies need to address the
question whether it is possible to induce clinical improvement in
non-responders with persistent B cells and plasma cells in the
synovium.Conceivably, asubsetof patientswould benefit froma
moreintensedosingschedule.Itisalsopossiblethatpersistenceof
plasma cells in non-responders is related to the presence of long-
lived plasma cells in the synovium of a subset of patients. Plasma
cells with different longevity could be induced by mechanisms
such as epitope spreading. For these patients alternative
approaches may be considered, interfering with, for example,
APRIL (a proliferation-inducing ligand) and B lymphocyte
stimulator (BLyS). The present study strengthens the rationale
for evaluating changes in biomarkers after targeted therapies
interfering with B cells and plasma cells to further optimise the
clinical response in the context of personalised medicine.
The relationship between the change in plasma cells and
clinical improvement suggests that rituximab exerts its effects
at least in part by an indirect effect on short-lived autoreactive
plasma cells that are associated with the production of
autoantibodies. Consistent with these results, there was a
reduction in RF and ACPA levels after treatment; the reduction
in plasma cells was directly related to the decrease in ACPA
levels at week 16. These data are also in agreement with a
previous study showing a trend towards lower synovial
immunoglobulin synthesis 2 months after rituximab treatment,
although that study was not powered to detect statistically
significant changes.
5 A role for autoantibodies in RA has been
suggested since the discovery of RF in RA and regained interest
in the late nineties.
20 The previously reported decrease in RF and
ACPA levels after rituximab treatment relative to minor
changes in total immunoglobulins suggests a role for short-
lived plasma cells in their production.
232 8 This notion is
supported by observations in a mouse model; rheumatoid factor
transgenic mice were crossed with mice of the autoimmune-
prone MRL/lpr strain, after which a spontaneous rheumatoid
factor response developed. This response was mediated by
continuous generation of short-lived plasmablasts.
19 In addition,
it has been suggested that small immune complexes containing
autoantibodies may drive synovial inflammation by triggering
Figure 3 Differences in synovial B cells at baseline (A), respectively
changes in B cells after rituximab treatment (B and C), in clinical
responders versus non-responders. There was no statistically significant
difference in B cell numbers at baseline or in the reduction in synovial B
cells between responders and non-responders. The circles represent
outliers (values of more than 1.5 box lengths from the upper or lower
edge of the box; the box length is the interquartile range). *p,0.05,
**p,0.01.
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cells (A), intimal macrophages (C),
sublining macrophages (E) and T cells (G)
at baseline respectively changes in these
cells (B, D, F, H) after rituximab treatment
in clinical responders versus non-
responders. There was no statistically
significant difference in these cells at
baseline between responders versus non-
responders. In light of the kinetics of the
changes after treatment (fig 2), we
compared the decrease in synovial cell
populations other than B cells between
4 weeks and 16 weeks in relationship to
clinical response. There was a highly
significant difference in reduction of
intimal macrophages (p=0.008),
respectively plasma cells (p=0.002),
between responders compared to non-
responders with a similar trend for
sublining macrophages. The circles
represent outliers (values of more than
1.5 box lengths from the upper or lower
edge of the box; the box length is the
interquartile range). *p,0.05, **p,0.01.
Extended report
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29
The results presented here would support the concept that
autoantibody production by B cells and plasma cells is critically
involved in promoting synovial inflammation.
Depletion of B cells did not only indirectly result in a decrease
in synovial plasma cells, but there was also an effect on other
major cell populations, such as T cells and macrophages. This
indicates that B cells have an important role in sustaining the
inflammatory cell infiltrate in the rheumatoid synovium. The
decrease in synovial T cells and the disruption of lymphocyte
aggregates and germinal centres, as shown by the disappearance
of FDCs, supports the hypothesis that B cells influence T cell
activity and organisation in the synovial tissue. Lymphocyte
aggregates could be disrupted by the absence of B cell derived
factors such as lymphotoxin beta.
30 However, it is quite likely
that the explanation is more complex, since previous work has
shown that, in contrast to large follicles, relatively small
lymphocyte aggregates usually contain very few B cells.
31
Interestingly, B cell depletion also diminished macrophage
infiltration, which is in agreement with the concept that there
is a consistent relationship between clinical improvement and
changes in synovial macrophages, independent of the primary
mechanism of action of the treatment.
32 33 Together, the change
in T cells and macrophages could be explained by an indirect
effect of B cell depletion on the expression of proinflammatory
cytokines and chemokines involved in cell migration and
retention, although this remains to be shown.
In conclusion, rituximab treatment results in a variable
response on synovial B cells with secondary changes in numbers
of other inflammatory cells, leading to diminished synovial
inflammation. There is a direct relationship between the decrease
in synovial plasma cells and clinical improvement over time.
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